- Email: [email protected]
Epimacular Membrane Detachment Following Intravitreal Bevacizumab for Retinal Vasoproliferative Tumor
Ophthalmology Volume 124, Number 5, May 2017 Footnotes and Financial Disclosures Originally received: August 12, 2016. Final revision: December 4, 2016. Accepted: January 9, 2017. Available online: March 22, 2017.
operational infrastructural support from the Victorian government. These funding organizations had no role in the design or conduct of this research. Author Contributions: Manuscript no. 2016-69.
1
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
2
National Eye Institute, National Institute of Health, Bethesda, Maryland.
3
Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia. Financial Disclosure(s): Supported by the World Health Organization, Geneva, Switzerland (under National Institutes of Health, Bethesda, MD, contract no. N01-EY-2103) and by the Fundamental Research Funds of the State Key Laboratory in Ophthalmology at the Zhongshan Ophthalmic Center. Dr He receives support from the University of Melbourne Research at Melbourne Accelerator Program Professorship, National Natural Science Foundation of China (81420108008), Science and Technology Planning Project of Guangdong Province (2013B20400003). The Centre for Eye Research Australia receives
Conception and design: Ellwein, He Analysis and interpretation: Han, Ellwein, Guo, He Data collection: Han, Guo, Hu, He Obtained funding: Not applicable Overall responsibility: Han, Ellwein, Guo, Hu, Yan, He Abbreviations and Acronyms: BCNVA ¼ best-corrected binocular near visual acuity; BCNVI ¼ bestcorrected binocular near vision impairment; NVA ¼ near visual acuity; NVI ¼ near vision impairment; UCNVA ¼ uncorrected binocular near visual acuity; UCNVI ¼ uncorrected binocular near vision impairment. Correspondence: Mingguang He, MD, PhD, Centre for Eye Research Australia, Peter Howson Wing, Level 7, 32 Gisborne Street, East Melbourne, Victoria, 3002. E-mail: [email protected].
Pictures & Perspectives Epimacular Membrane Detachment Following Intravitreal Bevacizumab for Retinal Vasoproliferative Tumor A 38-year-old man complained of metamorphopsia in his left eye for 3 months with decreasing visual acuity to 20/100. Examination revealed epimacular membrane (Fig 1A) with a peripheral retinal vasoproliferative tumor. Spectral-domain optical coherence tomography (OCT) demonstrated a thick epimacular membrane (Fig 1B). Fluorescein angiography showed hyperfluorescence within the retinal vasoproliferative tumor (Fig 1C). He received an intravitreal bevacizumab injection. One month later, his metamorphopsia subsided. Three months later, his left eye vision was 20/20, and examination demonstrated the detached epimacular membrane floating in the posterior vitreous cavity (Fig 1D). Spectral-domain OCT showed restoration of normal contour and thickness of the macula without an overlying epimacular membrane (Fig 1E).
KUAN-JEN CHEN, MD NAN-KAI WANG, MD, PHD AN-NING CHAO, MD Department of Ophthalmology, Chang Gung Memorial Hospital, Chang Gung, University College of Medicine, Tayouan, Taiwan
742
operational infrastructural support from the Victorian government. These funding organizations had no role in the design or conduct of this research. Author Contributions: Manuscript no. 2016-69.
1
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
2
National Eye Institute, National Institute of Health, Bethesda, Maryland.
3
Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia. Financial Disclosure(s): Supported by the World Health Organization, Geneva, Switzerland (under National Institutes of Health, Bethesda, MD, contract no. N01-EY-2103) and by the Fundamental Research Funds of the State Key Laboratory in Ophthalmology at the Zhongshan Ophthalmic Center. Dr He receives support from the University of Melbourne Research at Melbourne Accelerator Program Professorship, National Natural Science Foundation of China (81420108008), Science and Technology Planning Project of Guangdong Province (2013B20400003). The Centre for Eye Research Australia receives
Conception and design: Ellwein, He Analysis and interpretation: Han, Ellwein, Guo, He Data collection: Han, Guo, Hu, He Obtained funding: Not applicable Overall responsibility: Han, Ellwein, Guo, Hu, Yan, He Abbreviations and Acronyms: BCNVA ¼ best-corrected binocular near visual acuity; BCNVI ¼ bestcorrected binocular near vision impairment; NVA ¼ near visual acuity; NVI ¼ near vision impairment; UCNVA ¼ uncorrected binocular near visual acuity; UCNVI ¼ uncorrected binocular near vision impairment. Correspondence: Mingguang He, MD, PhD, Centre for Eye Research Australia, Peter Howson Wing, Level 7, 32 Gisborne Street, East Melbourne, Victoria, 3002. E-mail: [email protected].
Pictures & Perspectives Epimacular Membrane Detachment Following Intravitreal Bevacizumab for Retinal Vasoproliferative Tumor A 38-year-old man complained of metamorphopsia in his left eye for 3 months with decreasing visual acuity to 20/100. Examination revealed epimacular membrane (Fig 1A) with a peripheral retinal vasoproliferative tumor. Spectral-domain optical coherence tomography (OCT) demonstrated a thick epimacular membrane (Fig 1B). Fluorescein angiography showed hyperfluorescence within the retinal vasoproliferative tumor (Fig 1C). He received an intravitreal bevacizumab injection. One month later, his metamorphopsia subsided. Three months later, his left eye vision was 20/20, and examination demonstrated the detached epimacular membrane floating in the posterior vitreous cavity (Fig 1D). Spectral-domain OCT showed restoration of normal contour and thickness of the macula without an overlying epimacular membrane (Fig 1E).
KUAN-JEN CHEN, MD NAN-KAI WANG, MD, PHD AN-NING CHAO, MD Department of Ophthalmology, Chang Gung Memorial Hospital, Chang Gung, University College of Medicine, Tayouan, Taiwan
742